CJC-1295 No DAC [10mg]

Published laboratory work has explored the compound's interaction with GHRH receptors on pituitary somatotroph cells, downstream activation of adenylate cyclase, and the resulting modulation of cyclic AMP-dependent growth hormone synthesis and release. Preclinical rodent models have examined GH and IGF-1 secretion dynamics, body composition parameters, and effects on bone mineral density in GH-deficient states. All findings referenced here derive from preclinical models and have not been validated in controlled human clinical trials.